This page shows the latest Denali Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Also working within the RIPK1 inhibitor space is Sanofi and Denali Therapeutics. ... In 2018, Sanofi paid Denali $125m upfront for access to two of the company’s RIPK1 inhibitors.
In August, Biogen signed an agreement with Denali Therapeutics for access to the latter’s Parkinson’s disease programme, fronting an initial $1bn for the deal. ... Denali’s portfolio of small molecule LRRK2 inhibitors and transport vehicle
Deal includes portfolio of small molecule LRRK2 inhibitors. Biogen has signed an agreement with Denali Therapeutics for access to the latter’s Parkinson’s disease programme, fronting an initial $1bn for ... Denali is also eligible to receive up to
Takeda Pharmaceuticals and Denali Therapeutics have entered a partnership to develop and commercialise therapies for multiple neurodegenerative diseases. ... At the forefront of the work will be Denali’s ATV technology, which aims to increase exposure
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Faced with that litany of failures, researchers are branching out beyond old approaches to amyloid- beta (Abeta) in search of effective therapeutics. ... Denali Therapeutics is collaborating with Sanofi on a drug designed to alleviate inflammatory
th. in the top deal makers of 2017, had a busy first week of the New Year, entering into an option and collaboration agreement with Denali Therapeutics paying $155m on agreement ... Acquisition company. 4, 800. Denali Therapeutics/ Takeda Pharmaceutical.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...